DMRA · DAMORA THERAPEUTICS INC
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Market Cap
1.393B
52 Wk Range
$15.76 - $38.33
Previous Close
$22.50
Open
$22.53
Volume
395,988
Day Range
$21.89 - $22.75
Enterprise Value
939.8M
Cash
528.5M
Avg Qtr Burn
-17.23M
Insider Ownership
8.41%
Institutional Own.
N/A
Qtr Updated
Sep 30th 2026
